Ovid Therapeutics Inc.
Ovid Therapeutics Inc. (Nasdaq: OVID) is a biopharmaceutical company developing small-molecule medicines for brain disorders, particularly conditions associated with neuronal hyperexcitability. Its pipeline targets epilepsies, seizures, psychoses, schizophrenia and mood disorders, with programs designed to modulate… From the company’s description.
Over the twelve months to Jun 30, 2026, Ovid Therapeutics Inc. reported revenue of $1.58M, down 76.2% from a year earlier, and a net loss of $34.49M. Operations used $54.77M in cash. In fiscal 2025, it reported revenue of $7.25M, up 1181.3% from fiscal 2024, and a net loss of $17.41M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Ovid Therapeutics Inc. does
In the company’s own words
Ovid Therapeutics Inc. (Nasdaq: OVID) is a biopharmaceutical company developing small-molecule medicines for brain disorders, particularly conditions associated with neuronal hyperexcitability. Its pipeline targets epilepsies, seizures, psychoses, schizophrenia and mood disorders, with programs designed to modulate neurotransmitters and ion channels. The lead clinical-stage candidate, OV329, is a GABA-aminotransferase inhibitor being developed for drug-resistant seizures, including focal onset seizures, tuberous sclerosis complex seizures and infantile spasms. Ovid is also advancing OV4071 and other compounds from a portfolio of direct KCC2 activators, initially focused on psychosis associated with Parkinson’s disease and Lewy body dementia. The company builds its pipeline through internal research, academic collaborations and licensing; its KCC2 portfolio was licensed from AstraZeneca, while OV329 originated under a Northwestern University license. Ovid has no reportable operating segments and has not established a commercial infrastructure; it outsources manufacturing and has 23 professionals. Its website is https://ovidrx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NEW YORK, NY
- Fiscal year end
- December
- CIK
- 1636651
- SIC
- 2834
Financial performance, year by year
Fiscal 2017–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Ovid Therapeutics Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Ovid Therapeutics Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Ovid Therapeutics Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Ovid Therapeutics Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Ovid Therapeutics Inc.'s last four quarterly filings that the numbers alone won't show?”